18F-FDG PET/CT in paediatric lymphoma: comparison with conventional imaging
- 321 Downloads
In children with Hodgkin’s disease and non-Hodgkin’s lymphoma, the ability of 18F-fluoro-2-deoxy-D-glucose PET/CT and conventional imaging (CI) to detect malignant lesions and predict poor lesion response to therapy was assessed and compared.
A retrospective review of findings reported on PET/CT and CI was performed using a lesion-based analysis of 16 lymph node and 8 extra-nodal regions. Lesions were defined by histopathological findings or follow-up > 6 months.
The study included 209 PET/CT scans with a valid CI comparator. A total of 5,014 regions (3,342 lymph node, 1,672 extra-nodal) were analysed. PET/CT performed significantly better than CI in the detection of malignant lesions with sensitivity and specificity of 95.9 and 99.7% compared to 70.1 and 99.0%, respectively. For predicting poor lesion response to therapy, PET/CT had fewer false-positive lesions than CI. The specificity for predicting poor lesion response to treatment for PET/CT was 99.2% compared to 96.9% for CI. PET/CT was the correct modality in 86% of lesions with discordant findings.
PET/CT is more accurate than CI in detecting malignant lesions in childhood lymphoma and in predicting poor lesion response to treatment. In lesions with discordant findings, PET/CT results are more likely to be correct.
KeywordsPaediatric lymphoma Sensitivity Specificity FDG PET/CT
Kevin London was gratefully supported by The Cancer and Research Support Fund, Oncology Unit, The Children’s’ Hospital at Westmead, Sydney, Australia.
Conflicts of interest
- 11.Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25(5):571–8.CrossRefPubMedGoogle Scholar
- 12.Friedman D, et al. AHOD0031: A phase III groupwide study of dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate risk Hodgkin disease. 2007, Children’s Oncology Group.Google Scholar
- 18.Partridge S, Timothy A, O’Doherty MJ, Hain SF, Rankin S, Mikhaeel G. 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin’s disease: influence on patient management in a single institution. Ann Oncol 2000;11(10):1273–9.CrossRefPubMedGoogle Scholar